The Insider: Meet the CEOs Webcast Replay
We were joined by the CEOs of ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.
- (ASX: PTX) Prescient Therapeutics Limited – Steven Yatomi-Clarke
- (ASX: EBR) EBR Systems Inc – John McCutheon
Recorded on 23rd August 2023 at 12pm (AEST).
FEATURED SPEAKERS
Steven Yatomi-Clarke
CEO and Managing Director - Prescient Therapeutics Limited (ASX: PTX)
Prescient Therapeutics is a clinical-stage oncology company that develops personalised therapies to treat cancer within the global US$280 billion (2021) oncology industry. Front and centre of the company’s aspirations is commercialising their targeted therapies, primarily PTX-100. The complete eradication of cancer in two patients, together with longer-than-expected durability of responses, has PTX-100 shaping up to be a game changer for T-cell lymphoma (TCL), an area of oncology with a sizable and under-served target market. There have been no serious adverse events related to PTX-100, and FDA allowance of the Phase 2 trial as a registration study would be a major milestone for the company, opening up a rapid pathway to commercialisation. Prescient also has two cell therapy platforms working to solve key problems in CAR-T. Prescient’s diversified pipeline of later stage and emerging assets were developed by and with world-class collaborators including Yale, the University of Pennsylvania, the Moffitt Cancer Centre and the Peter MacCallum Cancer Centre.
John McCutcheon
President & CEO - EBR Systems Inc (ASX: EBR)
EBR Systems provides safe, cost-effective and reliable therapies using wireless cardiac stimulation. The company’s WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle (LV). The WiSE technology platform provides EBR with a potential addressable market of US$2.1 billion. The company’s technology is protected by over 97 issued patents globally and currently has no direct competitors. In November 2022, WiSE technology was featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore, highlighting the technology’s position at the forefront of innovation in the cardiac rhythm management landscape. In June 2023, EBR Systems announced an AUD $35m capital raising, to ensure that EBR will be fully funded for its pathway to United States Food and Drug Administration (FDA) approval,commercial launch and sales growth through to H22025.
Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.
Past performance is not a reliable indicator of future performance.
Any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.
Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.
